Ibuprofen: safety and efficiency of its use in wide clinical practice

Cite item

Full Text


The paper presents data on the pharmacokinetics of the nonsteroidal anti-inflammatory drug ibuprofen and a review of the evidence base that suggests its clinical efficacy and safety in different categories of patients and discusses new, potentially possible indications for the use of this drug. Ibuprofen has marked anti-inflammatory, analgesic, and antipyretic effects, which along with its good tolerability, predictability of side effects, and a low risk of complications, allows it to be widely use in clinical practice. There are various ibuprofen formulations on the drug market. There may be not only an oral formulation of ibuprofen, but its topical (gel), rectal (suppositories), and parenteral (solution for intravenous injection) ones. More than 40 years' experience with ibuprofen used as an over-the-counter drug in wide clinical practice in approximately 80 countries worldwide serves as an illustrative example of the efficacy and safety of this agent.

Full Text

Ибупрофен: безопасность и эффективность применения в широкой клинической практике. - Аннотация. В статье приводятся данные по фармакокинетике нестероидного противовоспалительного средства (НПВС) ибупрофена, представлен обзор доказательной базы, свидетельствующей о его клинической эффективности и безопасности у пациентов разных категорий, обсуждаются новые, потенциально возможные показания к применению этого препарата. Ибупрофен оказывает выраженные противовоспалительное, анальгетическое и жаропонижающее эффекты, что в сочетании с хорошей переносимостью, предсказуемостью побочных эффектов и низким риском развития осложнений позволяет широко использовать его в клинической практике. На рынке лекарственных средств ибупрофен представлен разнообразными лекарственными формами. Возможны не только пероральный прием ибупрофена, но и местное (гель), ректальное (суппозитории) и парентеральное (раствор для внутривенного введения) применение. Более чем 40-летний опыт применения ибупрофена в широкой клинической практике почти в 80 странах мира в качестве безрецептурного препарата служит наглядным примером эффективности и безопасности этого препарата.


  1. Simmons D.L. Variants of cyclooxygenase-1 and their roles in medicine. Thromb Res 2003; 110 (5-6): 265-268.
  2. Rao P., Knaus E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J Pharm & Pharm Sci 2008; 11: 81s-110s.
  3. Herndon C.M., Hutchison R.W., Berdine H.J. et al. Management of Chronic Nonmalignant Pain with Nonsteroidal Antiinflammatory Drugs Joint Opinion Statement of the Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy 2008; 28 (6): 788-805.
  4. Henry D., Lim L.L-Y., Rodriguez L.G. et al. Variability in risk of gastrointestinal complications with individual NSAIDs: results of a collaborative meta-analysis. Br Med J 1996; 312: 1563-1566.
  5. Antman E.M., Bennett J. S., Daughertyet А. et al. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007; 115: 1634-1642.
  6. Vanderhoek J.Y., Bailey J.M. Activation of a 15-lipoxygenase/leukotriene pathway in human polymorphonuclear leukocytes by the anti-inflammatory agent ibuprofen. J Biol Chem 1984; 259: 6752-6756.
  7. Rainsford K.D. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 2009; 6: 275-342.
  8. Geisslinger G., Dietzel K., Bezler H. et al. Therapeutically relevant differences in the pharmacokinetical and pharmaceutical behavior of ibuprofen lysinate as compared to ibuprofen acid. Int J Clin Pharmacol Ther Toxicol 1989; 27 (7): 324-328.
  9. Schleier P., Prochnau A., Schmidt-Westhausen A.M. et al. Ibuprofen sodium dehydrate, an ibuprofen formulation with improved absorption characteristics, provides faster and greater pain relief than ibuprofen acid. Int J Clin Pharmacol Ther 2007; 45 (2): 89-97.
  10. Dewland P.M.P., Reader S., Berry Р. Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid incorporating poloxamer in healthy volunteers. BMC Clin Pharmacol 2009; 9: 19.
  11. Pavliv L., Voss B., Rock А. Pharmacokinetics, safety, and tolerability of a rapid infusion of i.v. ibuprofen in healthy adults. Am J Health-System Pharm 2011; 68 (1): 47-51.
  12. Kleinbloesem C.H., Ouwerkerk M., Spitznagel W. et al. Pharmacokinetics and bioavailability of percutaneous ibuprofen. Arzneimittelforschung 1995; 10: 1117-1121.
  13. Dominkus M., Nicolakis M., Kotz R. et al. Comparison of tissue and plasma levels of ibuprofen after oral and topical administration. Arzneimittelforschung 1996; 12: 1138-1143.
  14. Whitefield M., O, Kane C. J., Anderson S. Comparative efficacy of a proprietary topical ibuprofen gel and oral ibuprofen in acute soft tissue injuries: a randomized, double-blind study. J Clin Pharm Ther 2002; 27 (6): 409-417.
  15. Underwood M., Ashby D., Carnes D. et al. Topical or oral ibuprofen for chronic knee pain in older people. The TOIB study. Health Technol Assess 2008; 12 (22): iii-iv, ix-155.
  16. Solomon S.D., Wittes J. Finn P.V. et al. For the Cross Trial Safety Assessment Group. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117 (16): 2104-2113.
  17. Gislason G.H., Jacobsen S., Rasmussenet J.N. et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113: 2906-2913.
  18. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase. A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase. JAMA 2006; 296: 1633-1644.
  19. Zhang J., Ding E.L., Song Y. Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events Meta-analysis of Randomized Trials JAMA 2006; 296 (13): 1619-1632.
  20. Moore N., van Ganse E., Le Parc J.M. et al. The PAIN study: paracetamol, aspirin and ibuprofen new tolerability study. A large-scale, randomized clinical trial comparing the tolerability of aspirin, ibuprofen and paracetamol for short-term analgesia. Clin Drug Invest 1999; 18 (2): 89-98.
  21. Lesko S. M., Mitchell A.A. An assessment of the safety of pediatric ibuprofen: a practitioner-based randomized clinical trial. JAMA 1995; 273: 929-933.
  22. Aids for management of common headache disorders in primary care 2007. Доступно на: www.who.int/entity/mental_health/neurology/who_ehf_aids_headache.pdf
  23. Evers S., Afra J., Frese A. et al. EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force. Eur J Neurol 2009; 16 (9): 968-981.
  24. Rabbie R., Derry S., Moore R.A., McQuay H.J. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010; (10): CD008039.
  25. Verhagen A.P., Damen L., Berger M.Y. et al. Treatment of tension type headache: paracetamol and NSAIDs work: a systematic review. Ned Tijdschr Geneeskd 2010; 154: A1924.
  26. Suthisisang C., Poolsup N., Kittikulsuth W. et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 2007; 41 (11): 1782-1791.
  27. Silver S., Gano D., Gerretsen P. Acute treatment of paediatric migraine: a meta-analysis of efficacy. J Paediatr Child Health 2008; 44 (1-2): 3-9.
  28. Damen L., Bruijn J.K., Verhagen A.P. et al. Symptomatic treatment of migraine in children: a systematic review of medication trials. Pediatrics 2005; 116 (2): e295-302.
  29. Derry C., Derry S., Moore R.A., McQuay H.J. Single dose oral ibuprofen for acute postoperative pain in adults. Cochrane Database Syst Rev 2009; (3): CD001548.
  30. Hersh E.V., Kane W.T., O'Neil M.G. et al. Prescribing recommendations for the treatment of acute pain in dentistry. Compend Contin Educ Dent 2011; 32 (3): 22, 24-30; quiz 31-32.
  31. Ahmad N., Grad H.A., Haas D.A. et al. The efficacy of nonopioid analgesics for postoperative dental pain: a meta-analysis. Anesth Prog 1997; 44 (4): 119-126.
  32. Southey E.R., Soares-Weiser K., Kleijnen J. Systematic review and meta-analysis of the clinical safety and tolerability of ibuprofen compared with paracetamol in paediatric pain and fever. Curr Med Res Opin 2009; 25 (9): 2207-2222.
  33. Pierce C.A., Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother 2010; 44 (3): 489-506.
  34. WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses 2012. whqlibdoc.who.int/publications/2012/9789241548120_Guidelines.pdf
  35. Report of the WHO Expert Committee 2011 (including the 17th WHO Model List of Essential Medicines and the 3rd WHO Model List of Essential Medicines for Children) whqlibdoc.who.int/trs/WHO_TRS_965_eng.pdf
  36. WHO model formulary for children 2010.
  37. Konstan M.W., Byard P.J., Hoppel C.L., Davis P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332 (13): 848-854.
  38. Konstan M.W., Schluchter M.D., Xue W., Davis P.B. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176 (11): 1084-1089.
  39. Lands L.C., Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 2007; (4): CD001505.
  40. Konstan M.W., Krenicky J.E., Finney M.R. et al. Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. J Pharmacol Exp Ther 2003; 306 (3): 1086-1091.
  41. Gagne J.J., Power M.C. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010; 74 (12): 995-1002.
  42. Gao X., Chen H., Schwarzschild M.A., Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology 2011; 76 (10): 863-869.
  43. Samii A., Etminan M., Wiens M.O., Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009; 26 (9): 769-779.
  44. Baris D., Karagas M.R., Koutros S. et al. Nonsteroidal anti-inflammatory drugs and other analgesic use and bladder cancer in northern. New England Int J Cancer 2012; 132 (1): 162-173.
  45. Mahmud S.M., Franco E.L., Turner D. et al. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One 2011; 6 (1): e16412.
  46. Johnson C.C., Hayes R.B., Schoen R.E. et al. PLCO Trial Team. Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial. Am J Gastroenterol 2010; 105 (12): 2646-2655.
  47. Takkouche B., Regueira-Méndez C., Etminan M. Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 2008; 100 (20): 1439-1447.
  48. Zhao Y.S., Zhu S., Li X. et al. Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis. Breast Cancer Res Treat 2009; 117 (1): 141-150.
  49. Rainsford K.D. Fifty years since the discovery of ibuprofen. Inflammopharmacology 2011; 19 (6): 293-297.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies